293 related articles for article (PubMed ID: 23642267)
21. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
Wang XL; Feng ST; Chen B; Hu D; Wang ZZ; Zhang Y
Neurosci Lett; 2022 Mar; 774():136515. PubMed ID: 35149201
[TBL] [Abstract][Full Text] [Related]
23. Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets.
Uchida S; Tashiro T; Kawai-Uchida M; Mori A; Jenner P; Kanda T
J Pharmacol Sci; 2014; 124(4):480-5. PubMed ID: 24681641
[TBL] [Abstract][Full Text] [Related]
24. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
26. CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
Huang YX; Luo WF; Li D; Hu WD; Liu CF
Brain Res; 2011 Feb; 1376():113-21. PubMed ID: 21195062
[TBL] [Abstract][Full Text] [Related]
27. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?].
Ceiślak M; Komoszyński M
Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962
[TBL] [Abstract][Full Text] [Related]
28. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Hauser RA; Hubble JP; Truong DD;
Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
[TBL] [Abstract][Full Text] [Related]
30. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.
Hauser RA; Schwarzschild MA
Drugs Aging; 2005; 22(6):471-82. PubMed ID: 15974638
[TBL] [Abstract][Full Text] [Related]
31. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
33. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
[TBL] [Abstract][Full Text] [Related]
34. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.
Pinna A
CNS Drugs; 2014 May; 28(5):455-74. PubMed ID: 24687255
[TBL] [Abstract][Full Text] [Related]
35. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Huot P; Johnston TH; Koprich JB; Aman A; Fox SH; Brotchie JM
J Pharmacol Exp Ther; 2012 Aug; 342(2):576-85. PubMed ID: 22619253
[TBL] [Abstract][Full Text] [Related]
36. Anti-parkinsonian activity of the adenosine A
Ohno Y; Okita E; Kawai-Uchida M; Fukuda N; Shoukei Y; Soshiroda K; Yamada K; Kanda T; Uchida S
Eur J Pharmacol; 2023 Jul; 950():175773. PubMed ID: 37146707
[TBL] [Abstract][Full Text] [Related]
37. The effect of istradefylline for Parkinson's disease: A meta-analysis.
Sako W; Murakami N; Motohama K; Izumi Y; Kaji R
Sci Rep; 2017 Dec; 7(1):18018. PubMed ID: 29269791
[TBL] [Abstract][Full Text] [Related]
38. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
39. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
